Hematologic abnormalities during treatment with imatinib
| Parameter6-150 and grade6-151 . | All patients (n = 235) n (%) . | 400-mg dose group (n = 77) n (%) . | 600-mg dose group (n = 158) n (%) . |
|---|---|---|---|
| Anemia | |||
| Grade 3 | 77 (33) | 27 (35) | 50 (32) |
| Grade 4 | 15 (6) | 7 (9) | 8 (15) |
| Thrombocytopenia | |||
| Grade 3 | 73 (31) | 23 (30) | 50 (32) |
| Grade 4 | 29 (12) | 11 (14) | 18 (11) |
| Leukopenia | |||
| Grade 3 | 77 (33) | 21 (27) | 56 (35) |
| Grade 4 | 34 (14) | 14 (18) | 20 (13) |
| Neutropenia | |||
| Grade 3 | 55 (23) | 16 (21) | 39 (25) |
| Grade 4 | 82 (35) | 27 (35) | 55 (35) |
| Parameter6-150 and grade6-151 . | All patients (n = 235) n (%) . | 400-mg dose group (n = 77) n (%) . | 600-mg dose group (n = 158) n (%) . |
|---|---|---|---|
| Anemia | |||
| Grade 3 | 77 (33) | 27 (35) | 50 (32) |
| Grade 4 | 15 (6) | 7 (9) | 8 (15) |
| Thrombocytopenia | |||
| Grade 3 | 73 (31) | 23 (30) | 50 (32) |
| Grade 4 | 29 (12) | 11 (14) | 18 (11) |
| Leukopenia | |||
| Grade 3 | 77 (33) | 21 (27) | 56 (35) |
| Grade 4 | 34 (14) | 14 (18) | 20 (13) |
| Neutropenia | |||
| Grade 3 | 55 (23) | 16 (21) | 39 (25) |
| Grade 4 | 82 (35) | 27 (35) | 55 (35) |
Abnormalities occurring during treatment or worsening from baseline to the indicated grade.
CTC: NCI/NIH Common Toxicity Criteria include the following:
CTC grade 3: neutrophils 0.5 to less than 1.0 × 109/L; platelets 10.0 to less than 50.0 × 109/L; hemoglobin 65 to less than 80 g/L; leukocytes 1.0 to less than 2.0 × 109/L.
CTC grade 4: neutrophils less than 0.5 × 1009/L; platelets less than 10.0 × 109/L; hemoglobin less than 65 g/L; leukocytes less than 1.0 × 109/L.